Cefaz

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefaz

Property Description
Active Ingredient Ceftazidime
Form Sterile Powder for Injection
Pharmacological Class Third-generation Cephalosporin Antibiotic
Common Use Treating serious bacterial infections
Origin Semisynthetic

Cefaz is the trade name for a powerful anti-infective medicine whose active ingredient is Ceftazidime, a compound used to eliminate susceptible bacterial infections throughout the body. It belongs to the semisynthetic beta-lactam antibiotic family, specifically classified as a third-generation cephalosporin. The clinical profile of this drug highlights its exceptional activity against a wide range of clinically relevant Gram-negative pathogens, including Pseudomonas aeruginosa. Pharmacological studies have consistently confirmed this broad activity spectrum, establishing Ceftazidime as a reliable choice for treating these complex organisms. This specialized profile means Cefaz is generally reserved for managing more serious or complex systemic infections where targeted, high-efficacy microbial clearance is required, often administered in the hospital setting.


Composition and Form: What is Cefaz Made Of?

Cefaz is supplied as a sterile powder for injection, which is a parenteral dosage form that must be carefully reconstituted into a solution before administration. The primary component is the active drug Ceftazidime (often present as the pentahydrate), combined with specific excipients such as anhydrous sodium carbonate which ensures its stability and facilitates proper solubility during preparation. The necessity of this specialized dosage form means the drug must be delivered directly into the body, typically intravenously (IV) or intramuscularly (IM), to achieve the necessary systemic therapeutic concentration, a feature recognized for providing predictable bioavailability.


How Does Cefaz Function as a Bactericidal Agent?

The fundamental purpose of Cefaz is to act as a bactericidal agent, meaning its function is to actively kill susceptible bacteria outright, rather than merely halting their reproduction. This targeted, irreversible destruction of the pathogen is achieved by blocking the specific enzymes bacteria use to build and maintain their protective cell wall, ensuring rapid microbial clearance. This key bactericidal mechanism is clinically recognized as crucial for the management of serious, acute infectious diseases where rapid resolution of the bacterial load is paramount.

What side effects are possible with Cefaz?

Possible side effects and safety information

The safety profile of Cefaz (Ceftazidime) is characterized by adverse reactions grouped according to frequency and the body system affected, as documented in official regulatory labeling. This structure outlines both common, expected reactions and rare, serious safety concerns.


Frequency-Classified Adverse Reactions

Adverse effects are broadly classified across several System-Organ Classes (SOC), including Blood and Lymphatic System Disorders, Gastrointestinal Disorders, Immune System Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

  • Common Reactions (ge 1% to < 10%): These typically involve the blood (e.g., eosinophilia, thrombocytosis), the liver (transient enzyme elevations), the gastrointestinal system (diarrhea), and the injection site (e.g., phlebitis, pain/inflammation).
  • Uncommon Reactions (ge 0.1% to < 1%): These include minor hematological changes (leukopenia, neutropenia), candidiasis, abdominal pain, and transient increases in blood urea or creatinine. Clostridium difficile colitis is also listed in this frequency range.

Serious Safety Considerations

Official labeling highlights the risk of serious, though rare, reactions. These include life-threatening anaphylactic reactions and severe cutaneous adverse reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Of particular importance is the risk of neurological sequelae (seizures, myoclonus, encephalopathy). This risk is associated with excessive drug accumulation, making it a critical consideration for patients with renal impairment. The drug is substantially eliminated by the kidneys, and failure to reduce the dose in kidney disease increases the potential for these adverse events.

Safety Restrictions: Cefaz is contraindicated in individuals with a known hypersensitivity to Ceftazidime, any other cephalosporin, or a history of immediate and/or severe allergic reaction to any penicillin due to the risk of cross-sensitivity. Caution is advised when used concurrently with other nephrotoxic agents.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information describes Ceftazidime overdosage primarily by its potential for severe Central Nervous System (CNS) toxicity.

Documented Overdose Manifestations and Risks

Classification Documented Manifestations
CNS Toxicity Seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma are the primary signs documented in regulatory labeling.
Risk Factor Overdosage has occurred in and poses an increased risk to patients with renal impairment (kidney failure), as reduced clearance elevates drug concentrations.

Emergency Actions and Management

In the event of acute overdosage, immediate medical attention must be sought, and emergency services should be contacted. Regulatory documents state that since no specific antidote is known for Ceftazidime, the required management is based on careful observation and supportive treatment.

Procedurally, haemodialysis or peritoneal dialysis is noted to be a measure that can aid in the removal of the drug from the body following a massive overdose.

Therapeutic Uses of Cefaz

Quick Facts

  • Respiratory Tract Infections: May be used to address bacterial infections affecting the respiratory system.
  • Skin and Skin Structure Infections: Indicated for the management of certain bacterial infections of the skin and related tissues.
  • Urinary Tract Infections (UTIs): Used in the treatment of specific bacterial infections within the urinary system.
  • Infection Prophylaxis: May be administered to help reduce the risk of infection before and during certain surgical procedures.

What Cefaz treats: main uses and benefits

Cefaz is an established antibacterial agent that may be prescribed by a healthcare provider to manage a variety of infections caused by susceptible organisms. Its primary therapeutic domains include the treatment of bacterial infections in several body systems.

This medication is indicated for addressing respiratory tract infections, such as those that may affect the lungs, as well as infections of the urinary tract. It is also a treatment consideration for certain infections of the skin and associated soft tissues. Furthermore, Cefaz may be used in the management of bacterial infections affecting the biliary tract, the bone, and the joints.

Beyond treating established infections, Cefaz is also utilized for perioperative prophylaxis. This means it may be administered before and during certain surgical procedures to help reduce the incidence of specific postoperative infections in adult patients. The medication is used within these specific approved indications and therapeutic applications.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cefaz — Official Regulatory Information

The eligibility profile for Cefaz (Ceftazidime) is strictly defined by regulatory authorities based on a patient's medical history and current condition.

Contraindicated Populations (Absolute Non-Eligibility):

Contraindication Basis
Hypersensitivity to Ceftazidime or any other cephalosporin [FDA] Absolute prohibition due to allergy risk.
Severe hypersensitivity (e.g., anaphylaxis) to any other beta-lactam antibacterial (e.g., penicillins) [EMA] Prohibited due to documented risk of cross-hypersensitivity.

Age and Physiological Eligibility Status:

  • Age Groups: Use is established for adults and pediatric patients, including full-term neonates (from birth). For older adults (over 80 years), the daily dose should not normally exceed 3 g due to age-related reduced clearance [EMA].
  • Pregnancy and Lactation: Use during pregnancy is permitted only if the benefit is determined to outweigh the potential risk [FDA]. Use during lactation can be employed, as only small quantities are excreted in human milk [EMA].

Condition-Specific Eligibility Restrictions:

Condition Regulatory Restriction/Caution
Renal Impairment (CrCl leq 50 mL/min) Mandatory dose modification (reduction) is required to prevent neurological effects from high drug concentrations [FDA].
Gastrointestinal Disease Use requires caution, particularly for patients with a history of colitis [FDA].
Use-Not-Established The safety and efficacy of continuous infusion are not established for infants leq 2 months of age [EMA].

What should I know about interactions with other medicines?

Cefaz (Ceftazidime) has officially documented interaction patterns that primarily relate to substances affecting renal clearance, physical compatibility, and certain laboratory procedures.

Documented Drug and Substance Interactions

Interactions Affecting Exposure and Organ Function

Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as Aminoglycosides or potent Diuretics (e.g., Furosemide) may adversely affect renal function. This classification is a regulatory caution because impaired kidney function can increase the concentration of Ceftazidime in the body, which can be linked to a higher risk of neurological reactions.

Interactions Affecting Efficacy

Chloramphenicol is officially documented as being antagonistic in vitro with Ceftazidime. Due to the possibility of reduced efficacy, regulatory sources state that co-administration with Chloramphenicol should be avoided.

Timing and Physical Incompatibility

Ceftazidime is physically incompatible with Aminoglycosides. Regulatory guidelines strictly mandate that these two substances must not be mixed in the same solution for injection due requiring separate administration timing to avoid precipitation.

Procedural and Population-Specific Constraints

Interference with Laboratory Tests

Administration of Cefaz may cause a false-positive reaction for glucose in the urine when tests utilize copper reduction methods (such as CLINITEST® tablets). Furthermore, use is documented to cause a positive direct Coombs' test, which may interfere with blood cross-matching procedures.

Population-Specific Cautions

Regulatory documents highlight that the risk of central nervous system adverse reactions (toxicity), due to elevated Ceftazidime levels, is specifically heightened in patients with renal impairment. This is a label-based interaction constraint linked to the drug’s primary renal clearance.

Mechanism of Action

Irreversible Inactivation of Cell Wall Enzymes

Cefaz (Ceftazidime) functions as a bactericidal agent by directly disrupting the core machinery used by susceptible bacteria to maintain their structural integrity. Its primary action is the irreversible inhibition of essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs), particularly PBP-3. Ceftazidime acts as a suicide substrate, forming a permanent covalent bond with these enzymes, thereby blocking their ability to catalyze the final cross-linking step of peptidoglycan polymer assembly. This action shuts down the pathway responsible for building the rigid bacterial cell wall.

Triggering the Osmotic Lysis Cascade

The failure of cell wall assembly directly triggers a destructive physiological cascade. Without a strong, complete cell wall to withstand its high internal pressure, the bacterial cell immediately experiences osmotic instability. This causes the physical rupture of the cell membrane (cell lysis), resulting in the outright death of the microbe. This mechanism underpins the drug's classification as bactericidal.

Biological Constraints on Mechanistic Efficacy

The integrity of this mechanism is constrained by bacterial counter-defenses. Efficacy is reduced when pathogens produce beta-lactamase enzymes that chemically destroy the drug before it reaches the PBP targets, or when bacteria express efflux pumps that actively expel the drug, limiting the concentration available to initiate the bactericidal cascade.

Dosage and Administration Information

Cefaz (Ceftazidime) is administered exclusively via the parenteral route and is not formulated for oral use. The medicine is supplied as a sterile powder for injection that requires reconstitution with an appropriate diluent prior to use. Administration is typically performed as a slow intravenous (IV) injection over 3 to 5 minutes, or via a longer IV infusion. Intramuscular (IM) deep injection is an approved alternative route for specific indications.

Standard adult dosing is based on the condition being addressed, typically ranging from 1 g to 2 g per dose, delivered in divided doses every 8 or 12 hours. The general maximum daily dose is 6 g; however, doses up to 9 g may be used in specific complex infections, such as those associated with cystic fibrosis.

A critical procedural instruction involves mandatory dosage modification for patients with impaired kidney function. The dosing interval or the dose amount must be extended or reduced according to the patient's estimated Creatinine Clearance to prevent drug accumulation. Pediatric dosing is determined by weight in mg/kg. The treatment course is variable but usually lasts 7 to 14 days or continues for two days after the infection symptoms have cleared. These standard protocols define the use around maintaining precise drug levels through scheduled, parenterally administered doses, dictating a required in-clinic or hospital use context.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefaz (Ceftazidime)

This overview describes the clinical research conducted on Cefaz (Ceftazidime), summarizing the types of trials that have been performed, the outcomes researchers measured, and the patient groups that were included in the regulatory evidence. This information is drawn from authoritative scientific and governmental sources to provide context, but it does not offer any medical advice or treatment recommendations.


Evidence for Use in Complicated Urinary Tract Infections (cUTI)

The evidence base for Ceftazidime's use in severe urinary tract infections, which include acute kidney infection (pyelonephritis), primarily relies on Phase 3 Randomized Controlled Trials (RCTs). These short-term trials were used in research exploring temporary physiological imbalance in hospitalized adult populations. Research protocols were designed to measure two main outcomes: microbiological clearance and clinical cure. Findings describe patterns observed in the studies related to achieving clearance at a specific post-treatment appointment.

However, the most relevant recent evidence cited in regulatory documents often focuses on Ceftazidime used in a fixed-dose combination with another drug (avibactam), particularly for resistant pathogens. The reliance on combination data indicates limited information for Ceftazidime used as a single agent.


Evidence for Use in Complicated Intra-Abdominal Infections (cIAI)

Studies for complicated infections within the abdomen were primarily designed as Phase 3 RCTs. Because these infections typically involve multiple types of bacteria, research protocols specified that Ceftazidime was used alongside a separate drug to target anaerobic bacteria. The studies monitored patient outcomes related to functional imbalance and tracked whether patients achieved clinical cure without needing further antibiotic treatment. Regulatory reviews noted that the research describes group patterns related to these outcomes, and consequently, the findings contribute to the understanding of the full combination regimen.


What Is Still Uncertain About Cefaz Research

While established, the research landscape includes areas where data remain insufficient or uncertain:

  • Monotherapy Data: For several serious infections (cIAI, VAP), the most recent high-certainty evidence involves Ceftazidime used as a fixed-dose combination with another drug. This limits the scope of conclusions that can be drawn solely for Ceftazidime used by itself.
  • Subgroup Findings are Uncertain: Research on bloodstream infections (bacteremia) is derived from small, secondary analyses rather than dedicated RCTs. This small sample size and exploratory nature means that the evidence remains limited for bacteremia as a primary infection.

Key Studies & References Ceftazidime–Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections (Integrated Analysis of Phase 3 RCTs)

Frequently Asked Questions (FAQ)

Common questions about Cefaz (FAQ)


Q: How quickly does Cefaz usually start working after the first dose?

Cefaz is classified as a bactericidal medicine, meaning its function is to actively kill susceptible bacteria outright. Its mechanism involves working quickly to kill susceptible bacteria upon administration, though the evidence supporting its use describes measuring clinical cure and microbiological clearance days after the full treatment course begins.


Q: Is Cefaz the same kind of drug as penicillin?

Cefaz belongs to the cephalosporin class of antibacterial medicines. It is not identical to penicillin, but because both fall under the larger category of beta-lactam drugs, there is a potential risk of cross-hypersensitivity. For this reason, official regulatory documents state the drug is contraindicated if a patient has a history of a severe allergic reaction to penicillin.


Q: What are the signs of a severe allergic reaction to Cefaz?

Official labeling lists signs of an allergic reaction that are listed in official labeling as reasons to seek emergency care, such as a skin rash, hives, or difficulty breathing. More serious, though rare, reactions include life-threatening conditions like anaphylaxis and Stevens-Johnson Syndrome (SJS), which is typically identified by blistering and peeling of the skin.


Q: What should I do if I notice a change in my tongue while taking Cefaz?

Candidiasis, which is a fungal infection sometimes known as thrush that can affect the mouth or tongue, is listed in official documents as an uncommon adverse reaction. Any unexpected change like this is typically noted in official documents as a type of change to discuss with the prescribing healthcare provider.


Q: Can people with a history of seizures use Cefaz?

Official warnings caution about the risk of serious neurological events, including seizures, particularly when Cefaz levels are elevated due to impaired kidney function. Regulatory documents emphasize that a patient's full medical history, including any prior history of seizures, is essential information for the prescribing healthcare provider to review.


Q: What are the common signs that Cefaz is working for my infection?

The required duration of the treatment course is officially described as continuing until the patient's primary infection symptoms have cleared, plus an additional two days. The expected improvement, based on official treatment criteria, is generally the resolution of the original symptoms that necessitated the prescription.


Q: Why is the full course of Cefaz often required, even if I feel better early?

Official information emphasizes that the medicine is intended to achieve complete microbiological clearance, meaning the elimination of the susceptible bacteria entirely. Studies examine whether patient groups achieve a clinical cure after a full course of treatment, which highlights the importance of adhering to the prescribed duration for achieving full treatment success.


Q: What is the official recommended action if I experience diarrhea while on Cefaz?

Diarrhea is a common adverse reaction, but official documents also list an uncommon risk of severe Clostridium difficile colitis. Official warnings specify that persistent or severe diarrhea during or after treatment is a symptom that should be discussed with a healthcare provider.


Q: Can Cefaz cause changes in mood or confusion?

Official regulatory documents list neurological adverse reactions associated with Cefaz use. These can include conditions such as encephalopathy, which is a general term for brain disease that can involve symptoms like confusion. Other central nervous system events that may affect mental status are also described as rare risks.


Q: Can Cefaz be used for treating viral infections?

According to the official product information, the approved indication for Cefaz is strictly the treatment of susceptible bacterial infections. Official documents state that the drug should not be used for infections that are known or suspected to be caused by viruses.


Q: Are there any long-term effects associated with using Cefaz?

Cefaz is officially described for use in short-term, acute treatment, typically lasting 7 to 14 days. The safety data available in the regulatory labeling focuses on the experience observed in patient populations during and shortly after this short duration of therapy.


Q: Can Cefaz affect birth control pills?

Official drug interaction documents do not list an interaction between Cefaz and hormonal contraceptives, such as birth control pills, that would reduce their effectiveness. This indicates that no reduction in effectiveness from this interaction is documented in the product information.


Q: How long does Cefaz typically stay in your system after the last dose?

Pharmacokinetic studies summarized in the official reports show that the average half-life of Cefaz is approximately 1.9 hours in adults with normal kidney function. The half-life is the time required for half the amount of the drug to be eliminated from the body.


Q: Why is Cefaz sometimes prescribed for skin infections?

Cefaz is officially indicated in regulatory documents for the treatment of complicated skin and skin-structure infections caused by susceptible bacteria. This approval is based on clinical trials demonstrating its efficacy against the pathogens commonly involved in these serious conditions.


Q: What is the evidence level for Cefaz use in treating lung issues?

For some serious lung infections, such as Ventilator-Associated Pneumonia (VAP), the most recent high-certainty evidence often involves Cefaz used in a fixed-dose combination with another drug. Regulatory reviews indicate this limits the scope of conclusions that can be drawn solely for Cefaz used by itself.


Q: Are there any known interactions between Cefaz and alcohol?

Official drug interaction documents from governmental regulatory bodies do not list a specific interaction between Cefaz and the consumption of alcohol.


Q: What kind of research has been done on Cefaz for pediatric patients?

Clinical research, including trials for dosing and safety, has been conducted in pediatric populations, ranging from full-term neonates through adolescents. Official documents confirm the dosing for these patients is based on their weight in mg/kg.


Q: Can Cefaz be prescribed for preventative reasons (prophylaxis)?

Regulatory documents list the indications for Cefaz as the treatment of existing infections, such as those in the abdomen or lungs. The medicine is not officially indicated in the product label for use as surgical or medical prophylaxis (prevention).


Q: Does Cefaz interact with common pain relievers like ibuprofen?

Official documents do not list a specific drug interaction between Cefaz and common nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. The interactions documented primarily involve other nephrotoxic agents.


Q: Does Cefaz show up in drug screening tests?

The official labeling documents interference with specific laboratory tests, such as causing a positive direct Coombs' test and a false-positive urine glucose result using certain methods. Information is not provided in regulatory documents regarding interference with general drug screening tests.


Q: Can Cefaz be used to treat infections in the ear?

Cefaz is officially indicated in regulatory documents for the treatment of certain susceptible bacterial infections, which includes otitis media (middle ear infections) when administered through the appropriate parenteral route.


Q: What should I look out for regarding Cefaz and hydration?

Official warnings caution against the concurrent use of Cefaz with nephrotoxic medicinal products, such as potent diuretics, as this may adversely affect renal function. Since the medicine is primarily cleared by the kidneys, general health guidelines often emphasize the role of appropriate fluid intake.


Q: Is Cefaz safe for people who are allergic to sulfa drugs?

Official documents specifically contraindicate the use of Cefaz only for individuals with a known hypersensitivity to cephalosporins or other beta-lactam antibacterial medicines. There are no official warnings regarding cross-sensitivity or contraindications related to an allergy to sulfa drugs.


Q: Does Cefaz interact with herbal remedies or multivitamins?

Official drug interaction documents reviewed by regulatory authorities do not list known interactions between Cefaz and general multivitamins or common herbal remedies.


Q: Are there official guidelines on driving or operating machinery while taking Cefaz?

Because Cefaz use is associated with the rare risk of central nervous system adverse reactions, such as dizziness or seizures, official warnings state that the ability to drive or operate machinery may be impaired.


Q: Why is a prescription required for Cefaz?

Cefaz is classified as a prescription-only medicine due to the need for parenteral administration (injection or infusion). This route requires professional preparation and delivery, and its use necessitates clinical oversight for precise dosage modification based on the patient's kidney function.


Q: Can Cefaz be used for dental infections?

Regulatory documents do not list dental infections as an official indication for Cefaz. The approved uses focus on treating serious systemic infections, such as complicated infections in the skin, lungs, and abdomen.

How should Cefaz be stored and disposed of?

Storage and Disposal Requirements for Cefaz (Ceftazidime for Injection)

The storage requirements for Cefaz, which contains Ceftazidime, depend on its physical state (dry powder versus solution), according to regulatory labeling.

Storage Conditions

Product State Temperature Requirement Stability Limit
Dry Powder Controlled Room Temperature (20 C to 25 C) Protected from light
Reconstituted Solution Refrigerated (2 C to 8 C) 3 days
Reconstituted Solution Room Temperature (20 C to 25 C) 12 hours

Handling and Disposal

Solutions that have been thawed must not be refrozen, and rapid thawing using methods like water baths or microwaves is prohibited. Unused or expired medication must be disposed of in accordance with all local and national regulations, often requiring handling as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefaz found in:

A-Z Index: